Literature DB >> 10822035

Management of atrial fibrillation: therapeutic options and clinical decisions.

E N Prystowsky1.   

Abstract

Atrial fibrillation (AF) is the most common, sustained tachyarrhythmia seen in clinical practice. Although it is not immediately life threatening, AF can cause troublesome symptoms and poses a risk of stroke. The patient's clinical status is often complicated by the presence of other cardiovascular or concomitant diseases. As a result, management of the patient with AF involves many questions and choices, all of which must be individualized. There are 3 general strategies for the management of patients with AF, including (1) restoration and maintenance of sinus rhythm, (2) control of ventricular rate, and (3) prevention of stroke. More than 1 strategy may be appropriate in some patients. Furthermore, either pharmacologic or nonpharmacologic options can be chosen in certain situations. Although some data from randomized clinical trials are available to aid in clinical decision-making, only the benefits of anticoagulation are supported by substantial evidence. This article explores practical approaches to several management issues and scenarios for which there are limited relevant clinical data. These include: (1) patient selection for ventricular rate control and assessment of treatment, (2) choice of antiarrhythmic drug for maintenance of sinus rhythm, (3) inpatient versus outpatient initiation of therapy, (4) definition of antiarrhythmic drug success, (5) methods of transthoracic direct cardioversion, and (6) prediction and prevention of AF after cardiac surgery.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10822035     DOI: 10.1016/s0002-9149(00)00908-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  10 in total

Review 1.  Atrial fibrillation: is rate stabilization a valid clinical strategy?

Authors:  S H Hohnloser
Journal:  Ann Noninvasive Electrocardiol       Date:  2001-04       Impact factor: 1.468

2.  Incidence, Risk Factors and Outcomes of New Onset Supraventricular Arrhythmias in African American Patients with Severe Sepsis.

Authors:  O'Dene Lewis; Julius Ngwa; Richard F Gillum; Alicia Thomas; Wayne Davis; Vishal Poddar; George R Adams; Alvin Jr Thomas; Alem Mehari
Journal:  Ethn Dis       Date:  2016-04-21       Impact factor: 1.847

Review 3.  WITHDRAWN: Pharmacological cardioversion for atrial fibrillation and flutter.

Authors:  John Cordina; Gillian E Mead
Journal:  Cochrane Database Syst Rev       Date:  2017-11-15

4.  Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study.

Authors:  Dagmar Busse; Silke Templin; Gerd Mikus; Matthias Schwab; Ute Hofmann; Michel Eichelbaum; Kari T Kivistö
Journal:  Eur J Clin Pharmacol       Date:  2006-07-04       Impact factor: 2.953

5.  Treating critical supraventricular and ventricular arrhythmias.

Authors:  Hans-Joachim Trappe
Journal:  J Emerg Trauma Shock       Date:  2010-04

Review 6.  Have sanctioned algorithms replaced empiric judgment in the selection process of antiarrhythmic drugs for the therapy for atrial fibrillation?

Authors:  James A Reiffel
Journal:  Curr Cardiol Rep       Date:  2004-09       Impact factor: 2.931

Review 7.  Anti-thrombotic strategies for patients with atrial fibrillation and heart failure.

Authors:  Mary Norine Walsh; Eric N Prystowsky
Journal:  Heart Fail Rev       Date:  2002-07       Impact factor: 4.214

Review 8.  Update on anti-coagulation in atrial fibrillation.

Authors:  J Kreuzer
Journal:  QJM       Date:  2011-08-03

9.  Structures of the recurrence plot of heart rate variability signal as a tool for predicting the onset of paroxysmal atrial fibrillation.

Authors:  Maryam Mohebbi; Hassan Ghassemian; Babak Mohammadzadeh Asl
Journal:  J Med Signals Sens       Date:  2011-05

10.  Sequence to Sequence ECG Cardiac Rhythm Classification Using Convolutional Recurrent Neural Networks.

Authors:  Teeranan Pokaprakarn; Rebecca R Kitzmiller; J Randall Moorman; Doug E Lake; Ashok K Krishnamurthy; Michael R Kosorok
Journal:  IEEE J Biomed Health Inform       Date:  2022-02-04       Impact factor: 7.021

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.